

UNIFORM
NATIONAL RULES
REGARDING MEDICATION,
PENALTIES AND
LABORATORY
ACCREDITATION

Exhibit A
(8 Pages, Pages 1-8)
Controlled Therapeutic Medication Schedule
ARCI-011-020 Section C (1) (b)

A. Medication Restrictions

- (1) A finding by the commission approved laboratory of a prohibited drug, chemical or other substance in a test specimen of a horse is prima facie evidence that the prohibited drug, chemical or other substance was administered to the horse and, in the case of a post-race test, was present in the horse's body while it was participating in a race. Prohibited substances include:
 - (a) Drugs or medications for which no acceptable threshold concentration has been established;
 - (b) Controlled therapeutic medications in excess of established threshold concentrations or administration within the restricted time period as set forth in the ARCI Controlled Therapeutic Medication Schedule, Version 1.0, below.

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Acepromazine	10 ng/ml HEPS in urine	48 hours	Single IV dose of acepromazine at 0.05 mg/kg.	UC Davis project	Applicable analyte is metabolite HEPS
Betamethasone	10 pg/mL of plasma or serum.	7 days	IA administration of 9 mg of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP (American Regent product #0517-0720-01) ⁱ	RMTC study	IA dosing only - applicable analyte is betamethasone in plasma or serum
Butorphanol	300 ng/mL of total butorphanol in urine or 2 ng/mL of free butorphanol in plasma.	48 hours	Single IV dose of butorphanol as Torbugesic [®] (butorphanol tartrate) at 0.1 mg/kg.	J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2012.01385.x	Applicable analytes are total butorphanol (drug and conjugates) in urine and butorphanol in plasma (the drug itself, not any conjugate).

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Clenbuterol	140 pg/mL of urine or LOD in plasma or serum.	14 Days	Oral administration of clenbuterol as Ventipulmin [®] syrup (Boehringer-Ingelheim Vetmedica Inc., NADA 140-973) at 0.8 mcg/kg twice a day	<u>UC Davis</u> Boehringer-Ingelheim Vetmedica, Inc.	Applicable analyte is clenbuterol.
Dantrolene	100 pg/mL 5-hydroxydantrolene in plasma or serum	48 hours	Oral administration of 500 mg of dantrolene as paste (compounding pharmacy) or capsule formulation (Proctor and Gamble)	J. vet. Pharmacol. Therap. 34, 238–246	
Detomidine	1 ng/mL of carboxydetomidine in urine; LOD for detomidine in plasma.	72 hours	Single sublingual dose detomidine (Domosedan [®] gel at 40 mcg/kg)	Vet. J. 2012 Oct. 10 http://dx.doi.org/10.1016/j.tvjl.2012.08.016	

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Dexamethasone	5 pg/mL of plasma or serum	72 hours	IM and IV administration of dexamethasone sodium phosphate or oral administration of dexamethasone at 0.05 mg/kg. Regardless of route.	RMTC study	Applicable analyte is dexamethasone in plasma or serum
Diclofenac	5 ng/mL of plasma or serum	48 hours	Five inch ribbon topical application of 1% diclofenac liposomal cream formulation. (Surpass Topical Anti-Inflammatory Cream, IDEXX Pharmaceuticals)	<i>Veterinary Therapeutics</i> 6: 57-66 (2005)	Applicable analyte is diclofenac in plasma or serum.
DMSO	10 mcg/mL of plasma or serum	48 hours	Oral or IV	ARCI model rule	Applicable analyte is DMSO in plasma or serum.

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Firocoxib	20 ng/mL of plasma or serum	14 days	Oral administration of firocoxib as EQUIOXX oral paste at a daily dose of 0.1 mg/kg for four days	RMTC study	Applicable analyte is firocoxib in plasma or serum.
Flunixin	20 ng/mL of plasma or serum	24 hours	Single IV dose of flunixin as Banamine [®] (flunixin meglumine) at 1.1 mg/kg	ARCI model rule	Secondary anti-stacking threshold: 3.0 ng/mL in plasma (administration 48 hours prior).
Furosemide	100 ng/mL of plasma or serum	4 hours	Single IV dose of furosemide up to 500 mg	ARCI model rule	Must also have urine specific gravity < 1.010 for a violation.
Glycopyrrolate	3 pg/mL plasma or serum	48 hours	Single IV dose of 1 mg of glycopyrrolate as Glycopyrrolate Injection, USP (American Regent product # 0517-4601-25).	RMTC study; J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2011.01272.x	Applicable analyte is glycopyrrolate in plasma or serum.

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Ketoprofen	10 ng/mL of plasma or serum	24 hours	Single IV dose of ketoprofen as Ketofen [®] at 2.2 mg/kg	ARCI model rule	
Lidocaine	20 pg/mL of total 3OH-lidocaine in plasma	72 hours	200 mg of lidocaine as its hydrochloride salt administered subcutaneously	ESHLC data; Iowa State.	Applies to total major hydroxylated metabolite
Mepivacaine	10 ng/mL total hydroxymepivacaine in urine or above LOD of mepivacaine in plasma.	72 hours	Single 0.07 mg/kg subcutaneous dose of mepivacaine	EHSLC data	
Methocarbamol	1 ng/mL of plasma or serum	48 hours	Single IV dose of 15 mg/kg methocarbamol as Robaxin [®] or 5 grams orally.	University of Pennsylvania	Applicable analyte is methocarbamol in plasma or serum.

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Methylprednisolone	100pg/mL in plasma or serum	7 days	Total dose of Methylprednisolone acetate suspension in one articular space. ⁱⁱ The recommended withdrawal for methylprednisolone acetate is a minimum of 21 days at a 100mg dose.	RMTC February 2013 Directive	Applicable analyte is methylprednisolone.
Omeprazole	1 ng/mL of urine	24 hours	Single oral dose of omeprazole as Gastrogard® at 3.9 mg/kg		Applicable analyte is omeprazole sulfide in urine
Phenylbutazone	2 mcg/mL of plasma or serum	24 hours	Single IV dose of phenylbutazone at 2.2 mg/kg	ARCI model rule	Secondary anti-stacking threshold: 0.3 mcg/mL of plasma (Administration 48-hours prior).
Prednisolone	1 ng/mL serum or plasma	48 hours	1 mg/kg orally.		Applicable analyte is prednisolone in plasma or serum.

RCI SCHEDULE OF CONTROLLED THERAPEUTIC SUBSTANCES - Version 1.0

(Adopted April 2, 2013 by Racing Commissioners International.)

Controlled Therapeutic Substance:	Threshold:	No pre-race treatment within:	Dosing Specifications:	Reference Notes	Note:
Procaine penicillin <i>(administration must be reported to Commission)</i>	25 ng/mL Plasma	Following entry to race.	Intramuscular	RMTC – reference notes online.	Mandatory surveillance of horse at owner’s expense 6 hours before racing.
Triamcinolone acetonide	100 pg/mL of plasma or serum	7 days	Total dose of 9mg in one articular space. ⁱⁱⁱ	RMTC February 2013 Directive	Applicable analyte is triamcinolone acetonide in plasma or serum.
Xylazine	0.01 ng/mg of plasma or serum	48 hours	Intravenous		Applies to any xylazine and xylazine metabolite

ⁱ **Intramuscular** administration of **Betamethasone** will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

ⁱⁱ **Intramuscular** administration of **Methylprednisolone** will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

ⁱⁱⁱ **Intramuscular** administration of **Triamcinolone acetonide** will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

Exhibit B

(2 Pages, Pages 9-10)

Multiple Medication Violations Penalty System (MMV)

ARCI Model Rule: ARCI-011-020 Section B (13) (a)-(j)

(1) Multiple Medication Violations (MMV)

- (a) A trainer who receives a penalty for a medication violation based upon a horse testing positive for a Class 1-5 medication with Penalty Class A-D, as provided in the ARCI Uniform Classification for Foreign Substances, shall be assigned points based upon the medication's ARCI Penalty Guideline as follows:

Class	Points If Controlled Therapeutic Substance	Points If Non-Controlled Substance
Class A¹	N/A	6
Class B	2	4
Class C	1	2
Class D	½	1

- (b) The points assigned to a medication violation shall be included in the Stewards' or Commission Ruling. Such Ruling shall determine, in the case of multiple positive tests as described in paragraph (d), whether they shall thereafter constitute a single violation. The Stewards' or Commission Ruling shall be posted on the official website of the Commission and the official website of the Association of Racing Commissioners International. If an appeal is pending, that fact shall be noted in such Ruling. No points shall be applied until a final adjudication of the enforcement of any such violation.
- (c) A trainer's cumulative points for violations in all racing jurisdictions shall be maintained and certified by the Association of Racing Commissioners International. Once all appeals are waived or exhausted, the points shall immediately become part of the trainer's official ARCI record and shall then subject the trainer to the mandatory enhanced penalties by the Stewards or Commission as provided in this regulation.
- (d) Multiple positive tests for the same medication incurred by a trainer prior to delivery of official notice by the commission may be treated as a single violation.
- (e) The official ARCI record shall constitute prima facie evidence of a trainer's past record of violations and cumulative points. Nothing in this administrative regulation shall be construed to confer upon a licensed trainer the right to appeal a violation for

¹ Except for Class 1 and 2 environmental contaminants, *e.g.*, cocaine which shall be determined by the stewards based upon the facts of the case.

which all remedies have been exhausted or for which the appeal time has expired as provided by applicable law.

- (f) The Stewards or Commission shall include all points for violations in all racing jurisdictions as contained in the trainer’s official ARCI record when determining whether the mandatory enhancements provided in this regulation shall be imposed.
- (g) In addition to the penalty for the underlying offense, the following enhancements shall be imposed upon a licensed trainer based upon the cumulative points contained in his/her official ARCI record:

Points	Suspension in days
3-5.5	30
6-8.5	60
9-10.5	180
11 or more	360

MMP’s are not a substitute for the current penalty system and are intended to be an additional uniform penalty when the licensee:

- (i) Has more than one violation for the relevant time period, and
 - (ii) Exceeds the permissible number of points.
- (h) The suspension periods as provided above, shall run consecutive to any suspension imposed for the underlying offense.
 - (i) The Stewards’ or Commission Ruling shall distinguish between the penalty for the underlying offense and the enhancement based upon the trainer’s cumulative points.
 - (j) Any trainer who has received a medication violation may petition the ARCI to expunge the points received for the violation for the purpose of the MMV system only. The points shall be expunged as follows:

Penalty Classification	Time to Expungement
A	Permanent
B	3 years
C	2 years
D	1 year

